Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 6/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ACP1 | P24666 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110377 | 0.83 | MAPT (0.39) | BRD4SLC2A1MAPT | |
| SCHEMBL13685235 | 0.83 | PARP1 (0.33) | PARP1CYP2D6OPRK1 | |
| SCHEMBL13685233 | 0.83 | PARP1 (0.34) | PARP1CYP2D6OPRK1EPHB4 | |
| SCHEMBL2905425 | 0.82 | RECQL (0.34) | PARP1SLC2A1ALDH1A1LMNAGAA | |
| SCHEMBL12356714 | 0.72 | NCF1 (0.42) | BRD4POLBPARP14 | |
| SCHEMBL2901477 | 0.71 | BRD4 (0.32) | PARP1BRD4EPHB4 | |
| SCHEMBL2243192 | 0.69 | ACHE (0.42) | POLB | |
| SCHEMBL4596765 | 0.69 | ALDH1A1 (0.48) | PARP1BRD4CYP2D6POLBALDH1A1 | |
| SCHEMBL2245273 | 0.67 | BRD4 (0.41) | BRD4POLBALDH1A1LMNAGAA | |
| SCHEMBL13685486 | 0.67 | BRD4 (0.41) | BRD4POLBALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262774-B1 | 2-aminoquinolines as 5-HT5A receptor antagonists, their manufacture and pharmaceutical compositions thereof | HOFFMANN LA ROCHE (CH) | 2012-11-14 | — | — | EP | claimed |
| US-7989628-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | claimed |
| US-20090227628-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | claimed |
| EP-2262774-B1 | 2-aminoquinolines as 5-HT5A receptor antagonists, their manufacture and pharmaceutical compositions thereof | HOFFMANN LA ROCHE (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-7989628-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090227628-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227628-A1 | 2-AMINOQUINOLINES | HTR5A, HTR1A, HTR1E | PARP1 411/4885BRD4 2290/4885CYP2D6 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.